Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Adimmune Corp (4142:TWSE), powered by AI.
Adimmune Corp is currently trading at $17.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Adimmune Corp on Alpha Lenz.
View Adimmune Corp's valuation metrics on Alpha Lenz.
“Adimmune Corp's ROE is -4.7%. Explore profitability and growth together.”
Ask for details →Adimmune Corp is a biotechnology company focusing on the research, production, and distribution of vaccines. Established as a significant player within the pharmaceutical industry, its primary function is to develop vaccines that contribute to public health by preventing infectious diseases. The company is involved in producing seasonal influenza vaccines and is active in research for innovative vaccine solutions to tackle emerging health threats. Additionally, Adimmune Corp extends its operations to contract manufacturing services for other pharmaceutical companies, utilizing its advanced production facilities. The corporation plays a crucial role in the healthcare sector by ensuring the availability of critical vaccines, thus supporting global health initiatives. With a commitment to maintaining high-quality standards and deploying cutting-edge technology, Adimmune Corp is essential to the global supply chain for vaccines, thereby contributing to the mitigation of disease spread and the promotion of public health on an international scale.
“Adimmune Corp's ROE is -4.7%. Explore profitability and growth together.”
Ask for details →Adimmune Corp (ticker: 4142) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 17.5 with a P/E ratio of -x and P/B of -x.
ROE is -4.71% and operating margin is -22.94%. Annual revenue is $1.4B.